Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study.
J Atten Disord
; 28(5): 699-707, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38389266
ABSTRACT
OBJECTIVE:
Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited.METHODS:
We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children's-Sleep-Habits-Questionnaire (CSHQ).RESULTS:
1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found.CONCLUSION:
Our findings support that sleep-problems are common in ADHD, but don't suggest significant negative long-term effects of MPH on sleep.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Transtorno do Deficit de Atenção com Hiperatividade
/
Transtornos do Sono-Vigília
/
Estimulantes do Sistema Nervoso Central
/
Metilfenidato
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article